Waterstone Pharmaceutical (Wuhan) Co., LTD.
Quick facts
Phase 3 pipeline
- WS016 · Diabetes
WS016 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Waterstone Pharmaceutical (Wuhan) Co., LTD. portfolio CI brief
- Waterstone Pharmaceutical (Wuhan) Co., LTD. pipeline updates RSS
Frequently asked questions about Waterstone Pharmaceutical (Wuhan) Co., LTD.
What is Waterstone Pharmaceutical (Wuhan) Co., LTD.'s pipeline?
Waterstone Pharmaceutical (Wuhan) Co., LTD. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include WS016.
Related
- Sector hub: All tracked pharma companies